INT180338

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 2004
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 12
Total Number 13
Disease Relevance 6.87
Pain Relevance 4.09

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Cyp2d4) oxidoreductase activity (Cyp2d4) endoplasmic reticulum (Cyp2d4)
cellular_component (Cyp2d4) cytoplasm (Cyp2d4)
Anatomy Link Frequency
plasma 2
Cyp2d4 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Opioid 64 99.24 Very High Very High Very High
analgesia 18 98.96 Very High Very High Very High
Analgesic 66 98.28 Very High Very High Very High
tramadol 2 97.96 Very High Very High Very High
Codeine 18 97.44 Very High Very High Very High
Oxycodone 70 96.92 Very High Very High Very High
Morphine 44 95.16 Very High Very High Very High
tolerance 16 93.68 High High
sSRI 142 86.68 High High
Bioavailability 2 86.28 High High
Disease Link Frequency Relevance Heat
Autoimmune Hepatitis 1014 99.92 Very High Very High Very High
Hepatitis 108 99.72 Very High Very High Very High
Cognitive Disorder 38 99.36 Very High Very High Very High
Chronic Hepatitis 84 98.92 Very High Very High Very High
Infection 102 98.76 Very High Very High Very High
Hepatitis C Virus Infection 258 98.68 Very High Very High Very High
Sleep Disorders 24 98.40 Very High Very High Very High
Renal Failure 1 93.92 High High
Toxicity 16 90.92 High High
Autoimmune Disease 60 90.68 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Indeed, in a recent publication, pharmacokinetic interactions were found for citalopram due to CYP 2D6 (50).
CYP 2D6 Binding (interactions) of
1) Confidence 0.47 Published 2006 Journal International Journal of Clinical Practice Section Body Doc Link PMC1448696 Disease Relevance 0.06 Pain Relevance 0.35
The interactions with CYP 2D6 may be clinically significant not only for citalopram but also for escitalopram (51).
CYP 2D6 Binding (interactions) of
2) Confidence 0.47 Published 2006 Journal International Journal of Clinical Practice Section Body Doc Link PMC1448696 Disease Relevance 0.06 Pain Relevance 0.34
However, to the best of our knowledge, this is the first paper on a CYP2D6-mediated interaction between Flos carthami and Western drugs in vivo.
CYP2D6-mediated Binding (interaction) of
3) Confidence 0.37 Published 2011 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2994065 Disease Relevance 0.05 Pain Relevance 0.03
The antigenic sites on CYP2D6 autoantigen recognized by anti-LKM-1 autoantibodies are different in AIH-2 and HCV/anti-LKM-1 positive cases [92-95,101-104].
CYP2D6 Binding (recognized) of associated with autoimmune hepatitis and hepatitis c virus infection
4) Confidence 0.32 Published 2004 Journal J Autoimmune Dis Section Body Doc Link PMC544946 Disease Relevance 1.17 Pain Relevance 0
As stated for AIH-2, CYP2D6 is the major target autoantigen recognized by anti-LKM-1 autoantibodies in HCV patients [14,15,81-83,88,92-96].
CYP2D6 Binding (recognized) of associated with autoimmune hepatitis and hepatitis c virus infection
5) Confidence 0.32 Published 2004 Journal J Autoimmune Dis Section Body Doc Link PMC544946 Disease Relevance 0.91 Pain Relevance 0
M (following therapeutic dosing), indicating that CYP2D6 inhibition by tapentadol is unlikely to be clinically relevant.41
CYP2D6 Binding (indicating) of
6) Confidence 0.31 Published 2010 Journal Journal of pain research Section Body Doc Link PMC3004637 Disease Relevance 0 Pain Relevance 0.93
Many other opioids, including oxycodone, codeine, dihydrocodeine, hydrocodone, and tramadol, are primarily metabolized by the cytochrome P450 (CYP) enzymes CYP2D6 or CYP3A4.46 Mutations in the CYP2D6 gene, which occur in approximately 1% to 7% of the Caucasian population, can either decrease or increase enzyme activity, leading to alterations in opioid analgesia.47 The analgesic effects of codeine are highly dependent on conversion of codeine to morphine by CYP2D6; a poor CYP2D6 metabolic phenotype can suppress codeine analgesia, and an ultra-rapid CYP2D6 metabolic phenotype can lead to increased opioid effects, such as euphoria, dizziness, and visual disturbances.47
CYP2D6 Binding (leading) of associated with tramadol, oxycodone, analgesic, dizziness, opioid, morphine, analgesia and codeine
7) Confidence 0.31 Published 2010 Journal Journal of pain research Section Body Doc Link PMC3004637 Disease Relevance 0.27 Pain Relevance 2.21
For instance, CYP1A2 is the molecular target in dihydralazine-induced hepatitis and AIH as a component of APECED, CYP2D6 in AIH-2 and in some patients with HCV infection, CYP2A6 in APECED and in a proportion of patients with HCV infection and UGT1 in some cases of AIH-2 and chronic hepatitis D or C.
CYP2D6 Binding (component) of associated with chronic hepatitis, autoimmune hepatitis, hepatitis c virus infection, infection and hepatitis
8) Confidence 0.25 Published 2004 Journal J Autoimmune Dis Section Body Doc Link PMC544946 Disease Relevance 1.95 Pain Relevance 0.05
Recently, Klein et al [93] and Kerkar et al [94] reported another immunodominant epitope of CYP2D6 (amino acids 193–212) recognized in about 70% and 93 % of AIH-2 patients, respectively.
CYP2D6 Binding (recognized) of associated with autoimmune hepatitis
9) Confidence 0.24 Published 2004 Journal J Autoimmune Dis Section Body Doc Link PMC544946 Disease Relevance 0.38 Pain Relevance 0
The most immunodominant epitopes of CYP2D6 were amino acids 257–269 and 321–351, which are recognized in about 70% and 50% of AIH-2 cases, respectively [91,92].
CYP2D6 Binding (recognized) of associated with autoimmune hepatitis
10) Confidence 0.24 Published 2004 Journal J Autoimmune Dis Section Body Doc Link PMC544946 Disease Relevance 0.32 Pain Relevance 0
In addition, recent data provides convincing evidence that anti-LKM-1 autoantibodies recognize CYP2D6 exposed on the plasma membrane of hepatocytes from either AIH-2 or HCV/anti-LKM-1 positive patients [114,115] suggesting a pathogenetic role for these autoantibodies in hepatic tissue damage either in AIH-2 or in some cases of HCV/anti-LKM-1 positive patients [104,109,110,115].
CYP2D6 Binding (recognize) of in plasma associated with autoimmune hepatitis and hepatitis c virus infection
11) Confidence 0.24 Published 2004 Journal J Autoimmune Dis Section Body Doc Link PMC544946 Disease Relevance 0.71 Pain Relevance 0
Sertindole is metabolized in the liver by the cytochrome P450 isoenzymes CYP2D6 and CYP3A4 and has a plasma half-life of approximately three days.
CYP2D6 Binding (metabolized) of in plasma
12) Confidence 0.14 Published 2010 Journal Drug Design, Development and Therapy Section Body Doc Link PMC2939763 Disease Relevance 0.47 Pain Relevance 0.12
Ranolazine is extensively metabolized by CYP3A4 enzymes and, to a lesser extent, by CYP2D6.
CYP2D6 Binding (metabolized) of
13) Confidence 0.10 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2963161 Disease Relevance 0.51 Pain Relevance 0.07

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox